Behavioral demonstration of a reciprocal interaction between dopamine receptor subtypes in the mouse striatum: possible involvement of the striato-nigral pathway.
It is well known that stimulation of the D-2 dopamine receptor in vitro inhibits the increased efflux of cyclic adenosine monophosphate caused by D-1 receptor agonists. Furthermore, behavioral data suggest that the striato-nigral pathway is more involved with the dopamine agonist-induced expression of oral behaviors, which are, in turn, mediated by stimulation of the D-1 receptor. We examined an in vivo model to determine whether this D-1/D-2 reciprocal interaction is detectable at a behavioral level. First, mice were pretreated with wide range of doses of the D-2 antagonist, spiperone, and then injected with a behaviorally active dose of apomorphine (a nonspecific direct dopamine agonist) and were observed for incidence of oral behavior and rated for stereotypic behavior. A biphasic effect of spiperone pretreatment was observed, at some low doses both stereotypy and oral behavior were enhanced, while at high doses, both agonist-induced behaviors were progressively inhibited. To test the specificity of this effect for the striato-nigral pathway, mice were administered discrete electrolytic lesions in the ventral portion of the internal capsule in one hemisphere. The animals that responded to apomorphine by rotating ipsilaterally to the lesion were used in two, five-point apomorphine dose-response curves, one with, and one without, pretreatment with the dose of spiperone which most enhanced stereotypic behavior and incidence of oral behavior. The spiperone pretreatment caused a clear increase in the maximum rotational response to apomorphine without affecting the ED50. These data suggest that behavior associated with the striato-nigral efferent from striatum is marked by the opposition of D-1 and D-2 receptors.
Mandel
R J
RJ
Department of Medical Cell Research, University of Lund, Sweden.
Yurek
D M
DM
Randall
P K
PK
D000818:Animals; D001058:Apomorphine / Q000494:pharmacology*; D003342:Corpus Striatum / Q000187:drug effects / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D051379:Mice; D008810:Mice, Inbred C57BL; D009043:Motor Activity / Q000187:drug effects*; D011954:Receptors, Dopamine / Q000187:drug effects / Q000502:physiology*; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D012016:Reference Values; D013134:Spiperone / Q000494:pharmacology*; D013239:Stereotyped Behavior / Q000187:drug effects*; D013378:Substantia Nigra / Q000502:physiology*
D011954:Receptors, Dopamine; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D013134:Spiperone; D001058:Apomorphine